(GMT-05:00) Eastern Time (US & Canada)
45 minutes
There may never be another Operation Warp Speed, but are there strategies, tools, or tactics utilized during the rapid development of the COVID-19 vaccines and therapeutics that can be applied to drug development in other areas going forward? This panel of experts will explore that question and seek to identify how the drug development process can be improved to get new, safe and effective therapies and cures to patients faster.
There may never be another Operation Warp Speed, but are there strategies, tools, or tactics utilized during the rapid development of the COVID-19 vaccines and therapeutics that can be applied to drug development in other areas going forward? This panel of experts will explore that question and seek to identify how the drug development process can be improved to get new, safe and effective therapies and cures to patients faster.

Speakers

David Frey - Life Sciences Sector Leader for New England, KPMG
Dr. Patrick Verhoest - VP, Medicine Design, Pfizer
Dr. Siân Ratcliffe - VP, Head of Global Clinical Operations and interim Head of Analytics & Data Sciences, Biogen
Rohini Deshpande - Vice President, Drug Substance Technologies, Amgen
Sarah Rhee Lieber - VP & Head, North American Regulatory Affairs & Global Advertising/Promotion & Labeling, Sanofi
Tracks
Name Audience
Science Track